Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eucure Partners CD40 Antibody for Tri-Specific Drug with Korea’s ISU ABXIS

publication date: Nov 1, 2022

Eucure Biopharma, a Beijing antibody company, will collaborate with Korea’s ISU ABXIS to develop tri-specific antibodies for multiple cancer indications. ISU ABXIS will use Biocytogen’s humanized agonistic anti-CD40 antibody, which is currently in Phase II clinical trials, as the basis for the tri-specific drugs. Eucure will receive an upfront payment, milestone payments and royalties. Eucure is a subsidiary of Biocytogen, a company offering genetically-modified animal models. More details....

Stock Symbol: (KOSDAQ: 086890)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital